公开(公告)号：DE4425145A1

公开(公告)日：1996-01-18

申请号：DE4425145

申请日：1994-07-15

Applicant: BASF AG

Inventor： HELLENDAHL BEATE DR ,  LANSKY ANNEGRET DR ,  RENDENBACH-MUELLER BEATRICE DR ,  BACH ALFRED DR ,  UNGER LILIANE DR ,  TESCHENDORF HANS-JUERGEN DR ME ,  WICKE CARSTEN DR

IPC: C07D277/22 ,  A61K31/425 ,  A61K31/426 ,  A61K31/433 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/496 ,  A61K31/54 ,  C07D277/20 ,  C07D277/32 ,  C07D277/36 ,  C07D277/42 ,  C07D285/12 ,  C07D285/125 ,  C07D285/135 ,  C07D417/12 ,  A61K31/495 ,  C07D401/14

Abstract: The use is disclosed of thiazole and thiadiazole compounds having the formula (I), in which R , A, B and Ar have the meanings given in the description. These compounds have a high affinity to the dopamine D3 receptor and are therefore useful for treating diseases of the central nervous system.

公开(公告)号：CZ9797A3

公开(公告)日：1997-08-13

申请号：CZ9797

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE DR ,  LANSKY ANNEGRET DR ,  MUNSCHAUER RAINER DR ,  BIALOJAN SIEGFRIED DR ,  UNGER LILIANE DR ,  TESCHENDORF HANS-JURGEN DR ,  WICKE KARSTEN DR ,  DRESCHER KARLA DR

IPC: C07D249/08 ,  A61K31/41 ,  A61K31/435 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/505 ,  A61K31/53 ,  A61P1/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D249/12 ,  C07D249/14 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14

Abstract: PCT No. PCT/EP95/02781 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02520 PCT Pub. Date Feb. 1, 1996The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

公开(公告)号：CZ9700097A3

公开(公告)日：1997-08-13

申请号：CZ9797

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE DR ,  LANSKY ANNEGRET DR ,  MUNSCHAUER RAINER DR ,  BIALOJAN SIEGFRIED DR ,  UNGER LILIANE DR ,  TESCHENDORF HANS-JURGEN DR ,  WICKE KARSTEN DR ,  DRESCHER KARLA DR

IPC: C07D249/08 ,  A61K31/41 ,  A61K31/435 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/505 ,  A61K31/53 ,  A61P1/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D249/12 ,  C07D249/14 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14

CPC classification number: C07D403/12 ,  C07D249/12

公开(公告)号：DE4425146A1

公开(公告)日：1996-01-18

申请号：DE4425146

申请日：1994-07-15

Applicant: BASF AG

Inventor： HELLENDAHL BEATE DR ,  LANSKY ANNEGRET DR ,  RENDENBACH-MUELLER BEATRICE DR ,  BACH ALFRED DR ,  UNGER LILIANE DR ,  TESCHENDORF HANS-JUERGEN DR ME ,  WICKE CARSTEN DR

IPC: C07D233/84 ,  A61K31/33 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/495 ,  A61K31/496 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D213/56 ,  C07D213/64 ,  C07D213/65 ,  C07D213/70 ,  C07D213/73 ,  C07D213/79 ,  C07D213/81 ,  C07D233/90 ,  C07D307/79 ,  C07D333/24 ,  C07D333/28 ,  C07D333/38 ,  C07D471/18 ,  A61K31/52

Abstract: The present invention relates to the use of heterocyclic compounds of formula (I) Het - A - B - Ar in which Het A, B and Ar have the meanings given in the description. The compounds of the invention have a high affinity for the dopamine-D3-receptor and are therefore usable for the treatment of diseases responding to dopamine-D3-ligands.

公开(公告)号：DE4425144A1

公开(公告)日：1996-01-18

申请号：DE4425144

申请日：1994-07-15

Applicant: BASF AG

Inventor： HELLENDAHL BEATE DR ,  LANSKY ANNEGRET DR ,  MUNSCHAUER RAINER DR ,  BIALOJAN SIEGFRIED DR ,  UNGER LILIANE DR ,  TESCHENDORF HANS-JUERGEN DR ME ,  WICKE CARSTEN DR ,  DRESCHER KARLA DR

IPC: C07D249/08 ,  A61K31/41 ,  A61K31/435 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/505 ,  A61K31/53 ,  A61P1/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D249/12 ,  C07D249/14 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14

Abstract: The present invention relates to triazole compounds of formula (I) in which R , R stand for H or different substituents, A stands for a bivalent group, B stands for a rest of the formula (a), (b) or (c) and Ar stands for optionally substituted phenyl, pyridyl, pyrimidyl or triazinyl. The compounds of the invention have a high affinity for the dopamine-D3-receptor and are therefore usable for the treatment of diseases responding to dopamine-D3-ligands.